Literature DB >> 2944577

Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.

K Keyomarsi, R G Moran.   

Abstract

The effects of the fluoropyrimidines on leukemic cells of mouse and human origin have been studied in the presence of folinic acid. This reduced folate enhanced the cytotoxicity and the growth inhibitory potency of 5-fluorouracil (5-FUra) and of 5-fluoro-2'-deoxyuridine (FUdR) against all cell lines examined. The human leukemic cell lines used (two T- and two B-cells) were affected by these fluoropyrimidines only at substantially higher concentrations than were found to be inhibitory to mouse L1210 cells; however, the enhancement of the activity of the fluoropyrimidines occurred over the same range of folinic acid concentrations in mouse and human cells. Whereas the total intracellular folate pool increased continuously with every increment of folinic acid added to the medium, the enhancement of the potency of the fluoropyrimidines was limited. Augmentation of the effects of FUdR exceeded that of 5-fluorouracil in the human leukemic cells studied. The cytotoxicity of the fluoropyrimidines (as defined by cloning efficiency) was enhanced to a greater extent than was growth inhibition so that an impressive lethal synergism was noted; for instance, exposure of L1210 cells to nontoxic concentrations of 5-fluorouracil or FUdR in the presence of folinic acid resulted in a 98 or 99.9% cell kill, respectively. In contrast to previous predictions, the fluoropyrimidines were more inhibitory to mouse leukemic cells containing folate pools that were suboptimal for growth than for folate-replete cells. Growth rate experiments showed that cells exposed to moderate concentrations of FUdR were initially inhibited but recovered with time, whereas in cells exposed to both FUdR and folinic acid, the initial growth inhibitory effects were sustained. We conclude that folinic acid stabilizes the effects of the fluoropyrimidines on thymidylate synthase of both mouse and human leukemic cell populations and that this enhancement is reflected in both inhibition of the growth of and the lethality to these cells. We suggest that only doses of the fluoropyrimidines that are capable of initially inhibiting thymidylate synthase to a high degree will be synergistic with excess reduced folates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944577

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

Authors:  P P Lee; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Accumulation of tetrahydrofolates in human plasma after leucovorin administration.

Authors:  M A Bunni; B M Rembiesa; D G Priest; E Sahovic; R Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Efficacy of postoperative concurrent chemoradiation for resectable rectal cancer: a single institute experience.

Authors:  Joong Bae Ahn; Hee Chul Chung; Nae Choon Yoo; Jae Kyung Roh; Nam Kyu Kim; Chang Ok Suh; Gwi Eon Kim; Jin Sil Seong; Woong Ho Shim; Hyun Cheol Chung
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

5.  High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.

Authors:  V Gebbia; A Russo; N Gebbia; L Rausa; F Ingria; G Spatafora; G Zerillo; A Cimino; T Pastorello; P Ferrara
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

Authors:  G Milano; J L Fischel; M C Etienne; N Renée; P Formento; A Thyss; M H Gaspard; L Thill; D Cupissol
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.

Authors:  F M Muggia; A Tulpule; A Retzios; F Chen; S Jeffers; C G Leichman; L Leichman; C P Spears; K K Chan
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Authors:  C J Punt; P H de Mulder; J T Burghouts; D J Wagener
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Intrathecal 5-fluorouracil in the rhesus monkey.

Authors:  S L Berg; F M Balis; C L McCully; G A Parker; R F Murphy; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.